Maternal treatment with Hexoprenaline, a uterine relaxant, showed no adverse effects on infant development. Newborns and three-year-olds exposed to Hexoprenaline exhibited normal health and developmental findings.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Context:
Purpose:
Summary:
Impact: